Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PETX - Aratana Therapeutics Inc.


Previous close
4.92
4.920   100.000%

Share volume: 0
Last Updated: Wed 17 Jul 2019 10:00:00 PM CEST
Pharmaceuticals: Generic: 0.65%

PREVIOUS CLOSE
CHG
CHG%

N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
11%
Profitability 0%
Dept financing 8%
Liquidity 75%
Performance 8%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$4.92
P/E Ratio 
N/A
DAY RANGE
$4.92 - $4.92
EPS 
$0.00
52 WEEK RANGE
$3.30 - $7.16
52 WEEK CHANGE
$8.85
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,488,284
AVERAGE 30 VOLUME 
$850,576
Company detail
CEO:
Region: US
Website: https://www.aratana.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Generic
Sector: Health Technology

Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.

Recent news